- Home
- NUS vs CADL Comparison
NUS vs CADL Comparison
Compare NUS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUS | CADL |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.4M | 339.8M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NUS | CADL |
|---|---|---|
| Price | $9.62 | $5.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $7.00 | ★ $19.43 |
| AVG Volume (30 Days) | 439.5K | ★ 965.0K |
| Earning Date | 02-12-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $1,560,391,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | $4.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.32 | $4.25 |
| 52 Week High | $14.62 | $13.68 |
Technical Indicators
Market Signals| Indicator | NUS | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 51.59 |
| Support Level | $9.55 | $5.45 |
| Resistance Level | $10.35 | $6.14 |
| Average True Range (ATR) | 0.27 | 0.38 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 5.99 | 13.09 |
Price Performance
Historical ComparisonAbout NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.